Royalty Pharma Insider Sale: Urist Marshall’s 20,000‑Share Plan‑Based Sell
Royalty Pharma insider Urist Marshall sells 20,000 shares near $40.78, reflecting a structured plan‑based move amid a Teva partnership that could boost royalties and stock upside.
3 minutes to read